Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction

Journal of Clinical Epidemiology

Volumn 57, Issue 8, 2004, Pages 843-852

  Kent, David M ^a   Vijan, Sandeep ^b   Hayward, Rodney A ^b   Griffith, John L ^a   Beshansky, Joni R ^a   Selker, Harry P ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Activator; Clinical decision support; Cost benefit analysis; Economic models; Myocardial infarction; Patient selection; Streptokinase; Tissue plasminogen

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

AGED; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MYOCARDIAL INFARCTION; PATIENT SELECTION; SENSITIVITY AND SPECIFICITY; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 5644266123     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2004.01.008     Document Type: Article

References (15)

1. Fuchs V. The health sector's share of the gross national product. Science. 247:1990;534-538
2. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
3. Mark D.B., Hlatky M.A., Califf R.F., Naylor C.D., Lee K.L., Armstrong P.W., Barbara G., White H., Simoons M.L., Nelson S.L. Cost-effectiveness of thrombolytic therapy with tissue plaminogen activator compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424
4. Califf R.M., Stump D., Topol E.J., Mark D.B. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Am Heart J. 137:(5):1999;S90-S93
5. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C. Costeffectiveness in health and medicine. 1996;Oxford University Press, New York
6. Kent D.M., Hayward R.A., Griffith J.L., Vijan S., Beshansky J.R., Califf R.M., Selker H.P. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 113:2002;104-111
7. Selker H.P., Griffith J.L., Beshansky J.R., Schmid C.H., Califf R.M., D'Agostino R.B., Laks M.M., Lee K.L., Maynard C., Selvester R.H., Wagner G.S., Weaver W.D. Patient-specific predictions of outcomes in myocardial infarction for real time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 127:1997;538-556
8. Gurwitz J.H., Gore J.M., Goldberg R.J., Barron H.V., Breen T., Rundle A.C., Sloan M.A., French W., Rogers W.J. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 129:(8):1998;597-604
9. Selker H.P., Beshansky J.R., Griffith J.L., for the TPI Investigators. Use of the electrocardiograph-based thrombolytic predictive instrument (TPI) to assist thrombolytic and reperfusion therapy for acute myocardial infarction: A multicenter randomized clinical effectiveness trial. Ann Intern Med. 137:2002;87-95
10. Tung C.Y., Granger C.B., Sloan M.A., Topol E.J., Knight J.D., Weaver W.D., Mahaffey K.W., White H., Clapp-Channing N., Simoons M.L., Goore J.M., Califf R.M., Mark D.B. Effects of stroke on medical resource use and costs in acute myocardial infarction. Circulation. 99:(3):1999;370-376
11. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: A practical guide. Med Decis Making. 13:1993;322-338
12. AHFS drug information. 1999;Board of Directors of the American Society of Hospital Pharmacists, Bethesda, MD
13. Tsevat J., Goldman L., Soukup J.R., Lamas G.A., Connors K.F., Chapin C.C., Lee T.H. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 13:1993;161-165
14. Jaagosild P., Dawson N.V., Thomas C., Wenger N.S., Tsevat J., Knaus W.A., Califf R.M., Goldman L., Vidaillet H., Connors A.F. Jr. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Arch Intern Med. 158:(10):1998;1081-1089
15. Fuchs V.R. Health care and the United States economic system: an essay in abnormal physiology. Millbank Mem Fund Q. 50:1972;211-237